Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TBTC Study 25:A Prospective, Randomized, Double-Blind Study of the Tolerability of Higher Doses of Rifapentine

NCT00023426 is registered in ClinicalTrials.gov with Centers for Disease Control and Prevention as lead sponsor.

NCT NCT00023426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00023426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TBTC Study 25:A Prospective, Randomized, Double-Blind Study of the Tolerability of Higher Doses of Rifapentine
Lead sponsor
Centers for Disease Control and Prevention
Phase
Phase 2
Overall status
Completed
Start date
July 31, 1999
Completion date
February 28, 2003
Enrollment
150
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis